Addiction Scientists Urge Clinicians to Document Synthetic 7-OH Cases Separately from Natural Kratom

Why it matters

Clinicians who fail to distinguish concentrated synthetic 7-OH from natural kratom may miss diagnoses or apply inappropriate treatment — a gap that leading addiction scientists say is now costing lives.

The big picture

Concentrated synthetic 7-OH has emerged as a significant driver of opioid addiction cases at treatment centers across the U.S. While natural kratom leaf has an established use profile among an estimated 23 million Americans, concentrated synthetic 7-OH is 13 times more potent than morphine and has never been studied in humans. The FDA requested DEA scheduling in mid-2025, but the DEA has not yet acted, leaving the substance legally available in most states.

Key findings

• Five addiction researchers from UF, Mount Sinai, UT San Antonio, and University at Buffalo published a peer-reviewed editorial calling for urgent clinical documentation of 7-OH cases
• Concentrated synthetic 7-OH is 13 times more potent than morphine and is increasingly "masquerading as natural kratom" on product labels
• Los Angeles County identified six fatal overdoses tied to concentrated synthetic 7-OH in September–October 2025 alone
• FDA Commissioner Makary stated natural kratom leaf is "not our focus" — the concern is lab-made concentrated synthetic 7-OH products
• Authors urge clinics to add a separate intake form option for synthetic 7-OH, distinct from natural kratom, to build the evidence base the DEA needs to act
• FDA Adverse Event Reporting System (FAERS) and poison control centers have struggled to produce reliable data due to mislabeled products

What they say

"Concentrated synthetic 7-OH opioid products are not tested for safety, have never been studied in humans, and are far more dangerous than natural kratom leaf products, which have an established safety profile and are consumed by approximately 23 million Americans." — Gold et al., Substance Abuse and Rehabilitation, 2026

Bottom line

A group of leading addiction scientists is calling for a simple but urgent fix: add synthetic 7-OH as a distinct option on patient intake forms so clinicians stop misclassifying it as natural kratom — and so the DEA finally has the data it needs to act.